

**Summary of Utilization Management (UM) Program Changes**

**November 2020**

<b>Brand Name</b>	<b>Generic Name</b>	<b>Utilization Update Summary</b>	<b>Type</b>	<b>Effective Date</b>
<i>Stelara Quantity Limit Exception</i>	ustekinumab	<p>For the diagnoses of Crohn’s disease or ulcerative colitis, where the Stelara maintenance dose is being administered more frequently than the FDA approved dose, a member must try the standard dose for a minimum of 6 months. If a more frequent dose is requested, the dose must be found in manufacturer’s dosing information, a standard pharmacy resource for off-label dosing, or published clinical trial data.</p> <p>For continuation of a dosing interval more frequent than the standard, the member must have been taking the new dose for at least 6 months and have documented clinical benefit.</p>	New	1/01/2021
<i>Xyrem</i>	Sodium oxybate	Diagnosis of narcolepsy will require submission of medical records with the results of a sleep study to confirm diagnosis.	Update	2/01/2021